


**Survey of Gynecologic Oncologists
and General Medical Oncologists
March 3-5, 2025**

Topics of Interest in Ovarian Cancer (OC)

■ First choice GMOs ■ First choice GOs ■ Second choice GMOs ■ Second choice GOs

* Missing color = no respondents (0%)



ADC = antibody-drug conjugate; PROC = platinum-resistant OC; ICI = immune checkpoint inhibitor; AE = adverse event;
T-DXd = trastuzumab deruxtecan

How comfortable/familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research studies pertaining to the optimal selection of PARP inhibitors as part of up-front maintenance therapy for advanced OC?

GMOs

7%

43%

43%

7%

GOs

52%

32%

16%

Well informed

Uninformed

How comfortable/familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research studies pertaining to available clinical data evaluating PARP inhibitors in combination with ICIs for up-front treatment of advanced OC?

GMOs

7%

57%

20%

17%

GOs

4%

24%

36%

28%

8%

Well informed

Uninformed

How comfortable/familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research studies pertaining to the current clinical role of PARP inhibitors in relapsed OC?

GMOs

37%

50%

10% 3%

GOs

36%

20%

44%

Well informed

Uninformed

How comfortable/familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research studies pertaining to the optimal integration of mirvetuximab soravtansine into OC management algorithms?

GMOs

40%

47%

13%

GOs

28%

44%

24%

4%

Well informed

Uninformed

How comfortable/familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research studies pertaining to the implications of the recent FDA approval of T-DXd for pretreated HER2-positive solid tumors for the management of advanced OC?

GMOs

10%

43%

40%

7%

GOs

20%

36%

36%

8%

Well informed

Uninformed

How comfortable/familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research studies pertaining to early research findings with the novel ADC raludotatug deruxtecan for patients with pretreated PROC and ongoing evaluation of this agent in this setting?

GMOs

20%

33%

47%

GOs

16%

8%

24%

52%

Well informed

Uninformed

How comfortable/familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research studies pertaining to the observed activity and tolerability profile and continued Phase III evaluation of nemvaleukin alfa in combination with pembrolizumab for PROC?

GMOs

27%

13%

60%

GOs

4%

16%

20%

60%

Well informed

Uninformed

How comfortable/familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research studies pertaining to the diagnosis and management of AEs associated with commonly employed therapies for advanced OC?

GMOs

43%

47%

10%

GOs

24%

48%

20%

8%

Well informed

Uninformed